Pharmala Biotech (MDMA) Q1 2025 earnings summary

Executive summary

• Revenue exceeded CAD 1 million in fiscal 2024, up 95% year-over-year, driven by strong MDMA product sales, increased customer deposits, and resumed distribution with Rane Pharmaceuticals after a supply agreement termination.

• Q1 saw a slowdown in SAP revenue due to the distribution transition, but this was offset by strong growth in the Clinical Trial sales pathway and increased customer deposits reflecting future revenue tied to clinical trial and import permits.

• The company is actively seeking a U.S.-based distributor to streamline operations and reduce cross-border risks.

• Distribution operations for SAP were re-established and shipments to US clinical trials resumed.

Financial highlights

• Fiscal 2024 revenue exceeded CAD 1 million, up 95% year-over-year, with MDMA product sales growing by CAD 723,000, a 73% increase.

• Customer deposits rose to CAD 283,000 in Q1, up from CAD 208,000 at fiscal year-end, and increased by CAD 19,000 in fiscal 2024 and by CAD 74,000 in Q1.

• Revenue recognition is tied to product delivery, with deposits generally representing up to 50% of contract value.

• Q1 revenue was limited to license fees due to regulatory delays in shipments.

• Non-cash costs remained stable quarter over quarter despite team expansion.

Outlook and guidance

• Anticipates future revenue growth as new distribution partnerships and export permits enable product shipments, with increased inventory movement and shipments expected in future quarters.

• Expects to announce progress on non-dilutive funding for Phase 2 trials and preclinical development within the next quarter, though timelines may shift.

• Growth is expected to be driven by the Prescriber's Portal and new distribution partner, with long sales cycles but steadily expanding target markets.

• U.S. market seen as a key growth area, with increased government funding and clinical trial activity.